You are here

Article Text

Article menu
Download PDFPDF
Scientific correspondence
Intravenous immunoglobulin therapy for resistant ocular Behçet's disease
  1. Nir Seidera,
  2. Itzchak Beirana,
  3. Jehudith Scharfa,b,
  4. Benjamin Millera,b
  1. aDepartment of Ophthalmology, Rambam Medical Center, Haifa, Israel, bThe Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
  1. Itzchak Beiran, MD, Department of Ophthalmology, Rambam Medical Center, POB 9602, 31096 Haifa, Israel ibeiran{at}hotmail.com

Abstract

AIMS The present report was aimed at finding out whether gammaglobulin could have a role in treating ocular Behçet's disease (BD) refractory to accepted medical therapy.

METHODS Six eyes of four patients with ocular BD refractory to steroids and cyclosporin A were treated with a course of intravenous gammaglobulin and followed up for their response to treatment.

RESULTS All six eyes of all four patients showed good response to gammaglobulin therapy.

CONCLUSION Gamma globulin may have a role in treating refractory ocular BD. A wide range of controlled studies with longer follow up is needed to substantiate this impression.

  • immunoglobulin
  • Behçet's disease

https://doi.org/10.1136/bjo.85.11.1287

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes